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Association between obesity and cardiovascular diseases is well known, however increased
susceptibility of obese patients to develop several cancer types is not so commonly known.
Current data suggest that poorer overall survival in cancer patients might be associated to
non-cancer-related causes such as higher risk of cardiotoxicity in obese patients treated
with chemotherapeutic agents. Omentin, a novel adipokine decreased in obesity, is actually
in the spotlight due to its favourable effects on inflammation, glucose homeostasis and car-
diovascular diseases. Also, recent data showed that in vitro anthracycline-induced cardio-
myocyte apoptosis is counteracted by omentin suggesting its cardioprotective role.
Objective
Our aim was to evaluate omentin effects against docetaxel toxicity.
Results
Our data indicate that omentin inhibits docetaxel-induced viability loss and that increased
viability is associated to decreased caspase-3 expression and cell death. Although omentin
reduces NOX4 expression, it failed to reduce docetaxel-induced reactive oxygen species
production. Our results indicate that omentin decreases docetaxel-induced endoplasmic
reticulum stress, suggesting that cardioprotective role might be associated to ERS
inhibition.
Conclusion
These data suggest that omentin treatment may contribute to decrease susceptibility to
DTX-induced cardiotoxicity.
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Introduction
Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by
40% in the next decade [1]. A follow-up analysis from the Framingham study established obe-
sity as an independent risk factor for developing heart failure (HF), coronary artery disease
(CAD), stroke, and overall cardiovascular disease (CVD) death, but is also associated with a
higher prevalence of comorbidities such as diabetes, hypertension, and metabolic syndrome,
which finally increase the risk for CVD [2].
Although the association between obesity and CVDs is widely known, increased cancer
susceptibility of patients with obesity is not so commonly reported. Obesity has been
strongly associated with cancer occurrence [3], shorter time to recurrence and with
increased cancer-mortality [3, 4]. Current data indicate that poorer overall survival might
be associated to non-cancer-related causes such as higher probability of cardiac adverse
events in patients with obesity compared to lean subjects after treatment with chemothera-
peutic agents [5].
Steady progress in anticancer agents development has led to a significant increase in
patients survival from which has emerged the need to increase the knowledge of comorbidities
and medical complications associated or caused by chemotherapy treatments. Adverse cardio-
vascular events are the major cause of morbidity and mortality in early-diagnosed breast can-
cer survivors. A recent meta-analysis indicates that overweight and obesity are risk factors for
cardiotoxicity (CT) in breast cancer patients [6]. In addition, increased sensitivity to cardiac
systolic impairment and cardiomyocyte mitochondrial dysfunctions have been demonstrated
in murine models of obesity treated with anthracyclines [7, 8]. In opposition to the conven-
tional perspective as a passive reservoir for energy storage, adipose tissue is actually recognized
as an endocrine organ that expresses and secretes a variety of bioactive peptides, known as adi-
pokines, with deleterious or beneficial effects on cardiovascular system. Recent data placed the
altered endocrine function of adipose tissue in patients with obesity into the spotlight as a
potential mechanism in the relationship between obesity and CT [9, 10]. Among the “good”
adipokines, omentin (OMT) is actually attracting much attention due to its favourable effects
on inflammation, glucose homeostasis and CVD. Low levels of OMT are linked to CAD, HF,
acute myocardial infarction (AMI) and ischemic disease in patients with type 2 diabetes melli-
tus [11, 12]. In addition, regarding the mechanism of action at the molecular level of OMT,
Kataoka et al. described that through AMPK and Akt signalling, OMT is able to protect cardio-
myocytes from apoptosis ischemia/reperfusion injury [13]. It has been also reported that
plasma OMT-1 levels are significantly decreased in patients with obesity [14]. Recent data
showed that in vitro anthracycline-induced cardiomyocyte apoptosis is counteracted by OMT
through the inhibition of oxidative stress suggesting that defective levels of OMT in obese sub-
jects, in addition to obesity-related carcinogenesis, [15] might contribute to chemotherapy-
induced CT [10]. Although more recently developed chemotherapy agents are emerging less
cardiotoxic, it is being difficult to completely remove CT when using classic chemotherapy
[16]. Docetaxel (DTX) is a second-generation taxane, effectively used against different types of
cancers [17], that stabilizes the β-tubulin subunit of microtubules, preventing depolymeriza-
tion of the mitotic spindle. Taxanes promote bradi- and tachyarrhythmias, myocardic ische-
mia and heart failure [18, 19]. At molecular level, taxanes are capable to activate several
apoptosis pathways [17, 20]. Since OMT counteracts doxorubicin-induced apoptosis, the aim
of our study is to evaluate the possible cardioprotective effects of OMT against DTX-induced
apoptosis.
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Materials and methods
Cell culture and reagents
Rat ventricular cardiomyoblast cells (H9c2) were used as an alternative to primary cardiomyo-
cytes, these cells maintain morphological characteristics of immature embryonic cardiomyo-
cytes with electrical and hormonal signal pathway elements of adult cardiac cells [21], in
addition to energetic similarities to primary cardiomyocytes [22]. H9c2 were cultured in 0.1%
gelatine coated plates with DMEM medium (Sigma-Aldrich, St. Louis, MO, USA) supple-
mented with 10% fetal bovine serum (FBS), antibiotics (100 UI/mL penicillin, 100 μg/mL
streptomycin) and 2mM L-glutamine, in a 5% CO2 atmosphere at 37˚C. H9c2 were seeded at
least 24h before treatments unless otherwise indicated and the experimental procedures were
conducted upon reaching 80% confluence.
Cells were treated with OMT (Sigma-Aldrich, St. Louis, MO, USA), N-Acetyl-L-cysteine
(NAC) (Sigma-Aldrich) and DTX (Sigma-Aldrich, St. Louis, MO, USA) at indicated concen-
trations. Control groups were treated with respective culture medium and vehicle.
Flow cytometry analysis of ROS
H9c2 cells were incubated during 24 hours with 25nM DTX and/or 300ng/ml OMT and/or 1h
of pre-treatment with 4mM NAC in a 5% CO2 atmosphere at 37˚C. H9c2 cell cultures were
washed in PBS, trypsinized and resuspended in HBSS phenol-red-free medium (Sigma-
Aldrich) at 5×105 cells/ml. Samples were incubated at 37˚C in the dark with 5μM dihydroethi-
dium (DHE) for 30 min (Sigma-Aldrich). DHE is a specific biomarker of total superoxide
anion (O2
−). After incubation, cells were washed twice in cold PBS to eliminate excess staining
solution. ROS (O2
−) was measured by flow cytometry analysis of 5000-gated cells using FACS-
can and CellQuestPro software from Becton Dickinson (Fullerton, CA, USA) in channel FL2.
The autofluorescence in each sample was subtracted.
Cell viability
Cell viability was measured using the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium
bromide (MTT) assay (Sigma-Aldrich, St. Louis, MO, USA). Briefly, H9c2 cells were seeded at
a density of 5000 cells/well in 96-well plates. Cells were treated with 25nM DTX and/or 300ng/
ml OMT in a 5% CO2 atmosphere at 37˚C. After, MTT (0.5 mg/ml) was added and incubated
at 37˚C during 4 hours. Formazan crystals were solubilized with dimethyl sulfoxide (DMSO)
and isopropanol (1:1). The optical density (OD) was measured at a wavelength of 570nm and
690nm using an automated microplate reader.
Flow cytometry of apoptosis
Apoptosis was measured by using FITC Annexin-V-FLUOS staining Kit (Roche Diagnostics)
according to the manufacturer´s protocol. H9c2 cells were incubated during 24 hours with
25nM DTX and/or 300ng/ml OMT in a 5% CO2 atmosphere at 37˚C. Then, cells were col-
lected by trypsinization and centrifuged at 1200 rpm for 5 minutes. Following suspension in
binding buffer, cells were labelled with Annexin-V-FITC and Propidium Iodide (PI) according
to the manufacturer’s instructions. FITC and PI were measured by flow cytometry analysis of
5000-gated cells using FACScan and CellQuestPro software from Becton Dickinson (Fullerton,
CA, USA). Cells populations were defined as necrotic (PI+), apoptotic (AV+/PI+) or early
apoptotic (AV+) cells.
Omentin protects against docetaxel cardiotoxicity
PLOS ONE | https://doi.org/10.1371/journal.pone.0212782 February 22, 2019 3 / 16
Real-time quantitative PCR
Total RNA was isolated from cell culture using TRI Reagent (Sigma-Aldrich, St. Louis, MO,
USA), according to the manufacturer’s recommendations. First-strand cDNA was synthesized
from 1μg total RNA using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, MA,
USA), according to the manufacturer’s recommendations. The resulting cDNA was subjected
to Real-time PCR using FastStart Universal SYBR Green Master (Rox) (Roche Molecular Bio-
chemicals, Mannheim, Germany) was performed using specific primers (S1 Table). All reac-
tions were carried out in an Eppendorf Realplex termoclycler. Sample values were standardized
versus an indicated housekeeping gene.
Western blot
H9c2 cells were homogenized in ice-cold lysis buffer containing 50 mmol/l Tris-HCl, pH 7.5, 1
mmol/l EGTA, 1 mmol/l EDTA, 1% Triton X-100, 1 mmol/l sodium orthovanadate, 50 mmol/
l sodium fluoride, 5 mmol/l sodium pyrophosphate, 0.27 mol/l sucrose, 0.1% 2-mercaptoetha-
nol, and 1x Complete Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany)
for 1 hour. Homogenates were centrifuged at 21.100xg for 15 min at 4˚C; supernatants were
removed, and frozen at -20˚C. Cells lysates (15μg) were subjected to 13% acrylamide
SDS-PAGE gels, transferred on a PVDF membrane as previously described. Membranes were
blocked for 1 hour in TBS-Tween (TBST: 50mmol/l Tris-HCl, pH 7.5, 0.15mol/l NaCl and
0.1% Tween) containing 3% BSA and probed with primary antibodies (S2 Table). Detection of
proteins was performed using appropriate secondary antibody (S2 Table) and an enhanced
chemiluminescence reagent Pierce-ECL western blotting substrate (Thermo Scientific, MA,
USA).
Representative blots correspond to unedited images of full radiographic film detection.
Each band is accompanied by its respective load control.
Densitometry analysis was performed using ImageJ-1.33 software (NIH, Bethesda, MD,
USA). First, each blot is relativized to a background value obtained from an identical adjacent
area to consider any background variation in the radiographic signal. Each blot is then individ-
ually relativized versus its control to avoid any load variation between samples. Mean of 3 sam-
ples was used as experimental group value for each single experiment (n = 3).
Statistical analysis
Data are represented as mean ± SEM (standard error of the media). Statistical significance was
determined by Mann-Whitney, ANOVA followed by Tukey´s or Dunn´s post hoc test or two-
way Student’s t-test determined by using GraphPad Prism 6 Software. P<0.05 was considered
significant.
Results
Effects of DTX and OMT treatment in H9c2 cell viability and apoptosis
Viability of H9c2 cardiomyoblast cells was evaluated after 24h exposure to different concentra-
tions of DTX by using MTT assays. As shown in Fig 1A, docetaxel decreased H9c2 cell viability
in a dose-dependent manner. Based on the extremely significant decrease of the viability (Con-
trol; 1.00 ± 0.03, n = 8 vs. DXT; 0.71 ± 0.25, n = 8, Fig 1A), 25nM of DTX was selected as cardi-
otoxic concentration. H9c2 cells were co-treated with 300 ng/ml during 24h based on
previously described antiapoptotic role of omentin [23]. OMT counteracted DTX-induced
decrease in H9c2 viability (DTX; 0.76 ± 0.13, n = 3 vs. DTX+OMT (300 ng/ml); 0.97 ± 0.11,
n = 3, Fig 1B).
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Flow cytometry apoptosis assay showed that the treatment of H9c2 cells with DTX increases
necrosis and apoptosis compared to control group (Fig 1C and 1D). After 24 hours of OMT
co-treatment both necrosis (Control; 2.21 ± 0.23, n = 7 vs. DXT; 11.09 ± 1.95, n = 7 vs. DTX
Fig 1. Effect of OMT in viability, apoptosis and Caspase 3 expression in H9c2 cells exposed to DTX. (A) Histograms showing cell viability measured by
MTT assay in H9c2 cell treated with DTX after 24 h. (B) MTT cell viability assay in H9c2 cells treated with DTX and/or OMT after 24 hours. (C) Annexin V
flow cytometry assay on H9c2 cell treated with DTX and/or OMT. (D) Representative density-plots images of Annexin V-FITC/propidium iodide (PI) double
staining flow cytometry. (E) Caspase-3 levels in H9c2 cells treated with DTX and/or OMT after 24 hours. (F) Representative western blot autoradiographic
images. Data are expressed as mean ± SEM of three or four independent experiments. Statistical significance �, �� and ���p< 0.05, 0.01, and 0.001 vs. control;
#, ##, ### p< 0.05, 0.01 and 0.001 DTX-OMT vs. DTX.
https://doi.org/10.1371/journal.pone.0212782.g001
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+OMT; 6.84 ± 1.15, n = 7) and apoptosis (Control; 2.62 ± 0.28, n = 7 vs. DXT; 8.22 ± 0.48,
n = 7 vs. DTX+OMT; 3.63 ± 0.46, n = 7) have been significantly reduced. Early apoptosis was
not affected after any of the treatments (Fig 1C and 1D).
We next examined the effects of OMT co-treatment on DTX-induced caspase-3 activation
(ratio 17KDa/35KDa) as a major effector of cell death. H9c2 cardiac cells were co-treated with
OMT (300 ng/ml, 24h) and DTX. OMT counteracted caspase-3 activation induced by DTX
(DTX; 4.97 ± 1.37, n = 3 vs. DTX+OMT; 1.91 ± 0.44, n = 3, Fig 1E and 1F).
Effects of OMT on DTX-induced ROS production, NADPH oxidases, CAT,
GPx and SOD1 expression in H9c2 cells
Intracellular ROS levels were assessed by DHE in H9c2 cell treated with DTX and OMT.
While NAC supplementation significantly reduced ROS levels (NAC; 1.29 ± 0.14, n = 3 vs.
DTX; DTX+OMT; 6.64 ± 0.42 vs control and DTX, n = 3, Fig 2A and 2B); OMT co-treatment
does not affect DTX-induced ROS levels (DTX; 8.81 ± 0.64 relative to control, n = 3 vs. DTX
+OMT; 8.53 ± 1.60, n = 3, Fig 2A and 2B).
Previous data showed that DTX increase endothelial ROS formation through NOX4 [24].
However our results failed to show increased expression of studied NOX isoforms (NOX1,
NOX2 and NOX4) in DTX-H9c2 treated cells. Curiously, our results showed a marked
decrease in NOX4 expression in co-treated cells (DTX; 0.97 ± 0.06 vs. DTX+OMT; 0.80 ± 0.05,
Fig 2C) but any of the other analysed isoforms showed a regulation of gene expression after
co-treatment (data not shown). Our results suggest that increased ROS levels are not directly
associated with NOX isoforms expression.
Because DTX-induced toxicity is known to disturb the intracellular redox balance and to
cause oxidative stress in endothelial cells [24], antioxidant enzyme expressions including
superoxide dismutase 1 (SOD1), catalase (CAT) and glutathione peroxidase (GPx) were deter-
mined. As shown in Fig 3, statistical differences were found after DTX treatment in CAT and
GPX gene expression, but failed to show any difference in SOD1 expression. (Fig 3A–3C). We
have also analyzed SOD1, CAT and GPX protein expression; surprisingly we only found statis-
tical differences in SOD1 expression after DTX treatment (Fig 3D–3F). Catalase, SOD1 and
glutathione levels were not affected by OMT supplementation in H9c2 cells (Fig 3A–3F).
Effects of OMT on DTX-induced endoplasmic reticulum stress (ERS)
Due to the fact that ERS is one of the possible molecular mechanisms of cardiac toxicity [25,
26], we studied whether DTX induces ER stress in our in vitro model. Our results showed sig-
nificantly decreased expression of BIP in addition to increased expression of ATF6 and CHOP
indicating that DTX triggers ERS. We next examined if decreased cell death observed in H9c2
cells co-treated with DTX and OMT might be mediated by a reduction in ERS. Our data
showed that co-treatment with OMT counteract DTX-induced regulation of ERS genes. OMT
co-treatment, in addition to decrease CHOP and ATF6 and increase BIP expression, is capable
to induce overexpression of GADD34 (n = 3, Fig 4A–4F). We have also analysed protein,
according to gene expression analysis, we found that DTX-induced overexpression of ATF6α,
peIF2α/eIF2α and BIP is counteracted by OMT (n = 3, Fig 4G–4I).
Our data suggest that ERS relieve is not associated with quenching ROS excess by omentin
since co-treatment, in our conditions, counteracts ERS but does not reduce ROS levels. How-
ever, we wanted to assess this point by using pharmacological ROS scavenger NAC. Our data
show that reduction of oxidative stress associated with NAC treatment reduces gene expres-
sion of CHOP and protein of ATF6 induced by DTX, but not the other previously described
ERS proteins (n = 3, S1A–S1I Fig).
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Discussion
Worldwide obesity prevalence is estimated to reach 40% during the next decade. In addition
to contributing to cardiovascular disease, obesity has been strongly associated with increased
cancer incidence, particularly in postmenopausal women [3]. Although molecular mecha-
nisms linking obesity and cancer risk/prognosis are not fully elucidated, obesity creates a host
environment characterized by low-grade systemic inflammation, disturbed sex steroid signal-
ling and increased insulin/insulin-like growth factors that may promote malignant cell growth
and progression. Obesity is also associated with shorter time to disease recurrence, greater
mortality [3, 4] and is an important prognostic factor of cardiotoxic events independent of
treatment dose [27]. Recent data suggest that increased mortality in cancer patients might be
associated to non-cancer-related causes of death such as higher probability of cardiac adverse
events in patients with obesity treated with cardiotoxic agents [5].
Fig 2. Effect of OMT in ROS production and NADPH oxidase (NOX4) expression in H9c2 treated with DTX. (A) ROS levels determined by flow cytometry using
DHE staining in H9c2 cells treated with DTX and/or OMT after 24 hours and/or pre-treated with NAC for 1h. (B) Representative histogram images of DHE staining.
(C) Histograms showing NOX4 mRNA expression measured by real-time polymerase chain reaction in H9c2 cell treated with DTX after 24 h. Data represent the
means ± SEM from at least three independent experiments. Statistical significance �, �� and ���p< 0.05, 0.01, and 0.001 vs. control; #, ##, ### p< 0.05, 0.01 and 0.001
DTX-OMT vs. DTX.
https://doi.org/10.1371/journal.pone.0212782.g002
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Association between obesity and CVDs is well known for a long time, however increased
susceptibility of patients with obesity to suffer chemotherapy-induced adverse cardiac events
was not well documented until recently. An increased risk of CT as well as higher sensitivity to
systolic alterations and mitochondrial dysfunction associated to obesity has been demon-
strated in the last years, both in murine models [7, 8] and patients [6], respectively.
Although CT is not easily quantifiable, since most of available data comes from retrospec-
tive studies and only in a few cases a prospective evaluation of the cardiac function has been
performed, CT is identified as one of the most common complications of current cancer thera-
pies [28]. CT was commonly associated with the use of anthracyclines; however, lately breast
cancer cytostatic drugs have also been associated to cardiovascular toxicity [28]. Recent studies
suggest possible mechanisms by which CT trigger HF depending on the antineoplastic drug,
focusing the origin of CT in oxidative stress-induced cardiomyocyte apoptosis [29]. Cumula-
tive data suggest that mitochondrial cell damage is due to the formation of free radicals and
increased oxidative stress, decreased ATP levels, decreased expression of SERCA and ERS
induction, structural and functional damage that finally triggers cardiomyocyte death.
Several potential mechanisms such as overdose due to the adjustment to the real weight of
the patient [30] or genetic background [31], which also might explain significant co-
Fig 3. Effect of OMT in CAT, GPx and SOD1 antioxidant enzymes gene and protein expression in H9c2 treated with DTX. mRNA levels of (A) CAT, (B) GPx and
(C) SOD1 determined by real-time RT-PCR and protein levels of (D) CAT, (E) GPx and (F) SOD1 determined by Western blot in H9c2 cells treated with DTX and/or
OMT after 24 hours. Data represent the means ± SEM from at least three independent experiments. Statistical significance �, �� and ���p< 0.05, 0.01, and 0.001 vs.
control; #, ##, ### p< 0.05, 0.01 and 0.001 DTX-OMT vs. DTX.
https://doi.org/10.1371/journal.pone.0212782.g003
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occurrence of CVD with multiple types of cancers independently of behavioural risk factors
[32] have been suggested in the relationship between obesity and CT. Among them, changes
in the endocrine function of adipose tissue and circulating adipokine levels associated with
obesity seem to play a key role increasing the susceptibility to develop CT [9, 10].
Fig 4. Effect of OMT in ERS gene and protein expression in H9c2 treated with DTX. mRNA levels of (A) BIP, (B) CHOP, (C) ATF6, (D) XBP1, (E)
GADD34 and (F) MCPIP determined by real-time RT-PCR. Protein levels of (G) ATF6α, (H) peIF2α/eIF2α ratio and (I) BIP determined by western blot. All
experiments were performed in H9c2 cells treated with DTX and/or OMT after 24 hours. Data represent the means ± SEM from at least three independent
experiments. Statistical significance �, �� and ���p< 0.05, 0.01, and 0.001 vs. control; #, ##, ### p< 0.05, 0.01 and 0.001 DTX-OMT vs. DTX.
https://doi.org/10.1371/journal.pone.0212782.g004
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Recent data showed that in vitro anthracycline-induced cardiomyocyte apoptosis is coun-
teracted through the inhibition of oxidative stress by OMT [10], an adipokine released by vis-
ceral depots and down-regulated in patients with obesity [14]. Several studies show a tight
relationship between circulating OMT levels and cardiovascular health. Low levels of OMT are
linked with CAD, HF, AMI and ischemic disease in patients with type 2 diabetes mellitus [11,
12]. Previous reports have demonstrated a protective effect of OMT as therapeutic agent for
CVD [33]. As it was previously reported, OMT reduces apoptosis in H9c2 treated with doxo-
rubicin [10], it also reduces apoptosis in rat cerebral ischemic conditions [34] and in mice sub-
jected to myocardial ischemia followed by reperfusion [13]. In HUVEC cells, OMT increased
differentiation into vascular-like structures and decrease apoptotic activity under conditions of
serum starvation [35].
In this study, we demonstrated that OMT significantly reduces DTX-induced both necrosis
and apoptosis in H9c2 cardiomyoblasts, as it was shown with doxorubicin [10]. Our data dem-
onstrated a noticeable increase in oxidative stress and ERS in H9c2 cardiomyoblasts treated
with DTX, accompanied by a pronounced decrease in cell viability, as it was previously
described [24–26]. DTX induced caspase-3-dependent apoptosis was previously described in
human prostate cancer cell line [36], human oral squamous cell carcinoma cell lines [37],
breast and ovary carcinoma cells [38], but to the best of our knowledge, this is the first time
that direct action of DTX on H9c2 cells is associated with increased caspase-3 activity and
increased cell death.
Oxidative stress plays a central role in cardiomyocyte death in several adverse cardiovascu-
lar events [39]. NADPH oxidases (NOX) are the major source of O2– production, NADPH oxi-
dase 2 (NOX2) and 4 (NOX4) are both expressed in cardiac muscle. It has been previously
described that upregulation of NOX4 by hypertrophic stimuli increases apoptosis and mito-
chondrial dysfunction in cardiac myocytes. NOX4 has also been demonstrated to be an impor-
tant source of oxidative stress in the failing heart [40]. Previous data demonstrated that DTX
treatment increased NOX activity in HUVEC cells resulting in ROS formation [24] whereas
OMT inhibits NOX activity in vascular smooth muscle cells after tumour necrosis factor alpha
and platelet-derived growth factor treatment [23, 41]. We therefore studied whether DTX
might also caused an increase in oxidative stress that justify increased cardiomyocytes death
and whether OMT could also counteract the increase of stress as in vascular smooth muscle
cells. Our data demonstrated a significant increase in ROS formation in H9c2 cells treated
with DTX but failed to show any improvement after treatment with OMT despite the signifi-
cant decrease in NOX4 expression; NOX1 and NOX2 expressions were not affected in our
experimental model (data not shown). Although OMT may influence activity of alternative
endogenous anti-oxidative enzymes, including super oxide dismutase, catalase and glutathione
peroxidase [10], our data indicate that the decrease in cell death is not associated to a lower
oxidative stress since OMT does not counteract the increase in ROS levels. Oxidative stress,
caused by the overproduction of ROS and the decrease in the antioxidant level, is prevented or
suppressed by major antioxidant enzymes, including SOD, CAT and GPx. In our study, DTC
treatment increases CAT, GPX and SOD1 gene expression, probably as a compensatory
response against higher ROS levels or previously described reduced enzymatic activity associ-
ated to DTX treatment [42–44]. However, only in the case of SOD1 protein levels that increase
is significant. Coherently with the lack of omentin effect on oxidative stress, OMT did not play
any role on the expression of antioxidant enzymes in our model. Our data suggest that OMT
exerts its protective role through another pathway of damage.
Currently, ERS-mediated cardiomyocyte apoptosis has attracted broad attention, because it
has been found to be responsible for the pathophysiology of many CVDs [45]. The ER is an
organelle responsible of the folding of secretory and membrane proteins. Different stimuli
Omentin protects against docetaxel cardiotoxicity
PLOS ONE | https://doi.org/10.1371/journal.pone.0212782 February 22, 2019 10 / 16
cause the accumulation of unfolded and misfolded proteins, dissociating BIP from the three
ER transmembrane protein sensors PERKS, ATF6 and IRE1, triggering the unfolded protein
response (UPR) [46]. It has been recently published that after a strong or prolonged stimulus,
CHOP, caspase-12, and/or JNK-dependent apoptotic signalling pathways are activated. Thus,
CHOP apoptotic pathway activates caspase-3 related with Bcl-2 family proteins [45]. Previous
data demonstrated that DTX-induced apoptosis is mediated by induction of ERS [25]. Conse-
quently we analysed the expression of genes involved in ERS such as BIP, CHOP, ATF6, XBP1,
GADD34 and MCPIP in H9c2 DTX-treated cells and the effect of OMT co-treatment in ERS
gene expression. Although, conventionally ER stress response triggers upregulation of BIP
[46], our results showed a significant downregulated BIP expression counteracted by OMT.
However, according with conventional ERS response BIP protein levels increase after DTX
treatment and decrease after OMT/DTX cotreatment. CHOP is a molecule involved in ER
stress-induced apoptosis, under non-stressed conditions CHOP expression is low, but
increases in response to ER stress through IRE1-, PERK- and ATF6-dependent transcriptional
induction [47]. In addition, it has been proposed that ERS signalling, especially mediated by
ATF6, induces XBP1 [48] and plays a decisive role in the induction of apoptosis in muscle tis-
sues through activation of caspase-12 and subsequently activated caspase-3 [49]. Our results
showed a significant DTX-induced ATF6 upregulation, according to previous data in human
melanoma cells [25], accordingly to these results protein analysis also shows an increase in
ATF6α expression after DTX treatment and a decrease after OMT/DTX treatment, and a sig-
nificant increase in CHOP expression both counteracted after OMT treatment. Increased
ATF6 expression is accompanied by a slight, not significant increase, in XBP1 levels that is also
inhibited by OMT. Coherently with the role of the DTX as trigger of ERS and according with
previous data demonstrating that GADD34 is regulated by DTX in HL60 cells after 24 hours
[50], our data showed a marked decrease in GADD34 expression that is recovered when H9c2
are co-treated with OMT. As it was previously shown in prostate cancer cells, DTX treatment
in H9c2 cells also increases peIF2α/eIf2α protein expression, that is reduced after OMT co-
treatment [25, 26, 51]. In addition, our data showed also a non-significant increase in the
expression of the monocyte chemotactic protein-induced protein (MCPIP) inhibited by OMT.
Based on previous data, MCPIP up-regulation is probably associated with a previously
described increase in the expression of MCP1 [52] induced by the DTX [53].
Cumulative evidences support the perspective that oxidative and ER stress has a strong con-
nection. Reactive oxygen species are produced as by-products during the protein folding pro-
cess, impairing redox state, but also, impaired redox state leads to further ER stress since the
protein folding process is dependent on redox homeostasis. Therefore, in order to assess if
quenching of boosted ROS levels relief the observed ER stress, H9c2 cells were co-treated with
N-Acetylcysteine, a ROS scavenger, previously reported as cardioprotective agent against
anthracyclines induced toxicity [54]. Our data show that reduction of oxidative stress, associ-
ated with NAC pre-treatment, regulates changes in gene expression of CHOP and protein of
ATF6 induced by DTX, but not in the other ERS proteins analysed. Our data indicate that the
effects of omentin on ERS are not associated with the redox state [55].
In summary, our data showed that DTX has a direct effect on cardiomyoblasts, increasing
oxidative and ERS and consequently cell death, suggesting that it could play a direct role in the
development of myocardial toxicity. Our data does not clarify whether OMT counteracts or pre-
vents the onset of ERS, but clearly demonstrated that OMT, despite not reducing DTX-induced
oxidative stress, counteracts ERS and prevents apoptosis (Fig 5). These data suggest that omen-
tin treatment may contribute to decrease susceptibility to DTX-induced cardiotoxicity. The
results obtained in this study will be useful to carry out mechanistic in vivo model to explore the
possibility of using omentin as a treatment against the cardiotoxicity induced by docetaxel.
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Supporting information
S1 Fig. Effect of NAC in ERS gene and protein expression in H9c2 treated with DTX.
mRNA levels of (A) BIP, (B) CHOP, (C) ATF6, (D) XBP1, (E) GADD34 and (F) MCPIP deter-
mined by real-time RT-PCR. Protein levels of (G) ATF6α, (H) peIF2α/eIF2α ratio and (I) BIP
determined by western blot. All experiments were performed in H9c2 cells treated with DTX
after 24 hours and/or pre treated with NAC for 1 hour. Data represent the means ± SEM from
at least three independent experiments. Statistical significance �, �� and ���p< 0.05, 0.01, and
0.001 vs. control; #, ##, ### p< 0.05, 0.01 and 0.001 DTX-OMT vs. DTX.
(TIF)
Fig 5. Proposed mechanism of DTX induced cardiotoxicity: Involvement of ER stress. DTX induces BIP, CHOP, ATF6 expression and reduces GADD34
expression increasing phosphorylated eIF2a levels. Unresolved ER stress will eventually lead to cell death (caspase-mediated apoptosis). Rounded ends indicate
inhibitory pathways; arrows indicate stimulatory pathways.
https://doi.org/10.1371/journal.pone.0212782.g005
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S1 Table. Primers for real time qPCR analysis.
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S2 Table. Antibodies used in western blot analysis.
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Investigation: Ricardo Lage, Marı́a Cebro-Márquez, Moisés Rodrı́guez-Mañero, Isabel
Moscoso.
Methodology: Ricardo Lage, Marı́a Cebro-Márquez, Isabel Moscoso.
Project administration: Ricardo Lage, José Ramón González-Juanatey, Isabel Moscoso.
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